Between you and jandekkers posting the link that Dr. Tran works at AZN (who subsequently bought Neogene for a song) ... thanks and ... very good to know.

For Dr. Tran's success last spring at Providence Hospital in Oregon, an autologous, viral-vectored targeting of a patient with a single neoantigen is a challenge. The NCI still has its 2018 viral-vectored TCR-T trial open. For his work with Neogene science, Dr. Tran will be evaluating CRSPR science for vectoring.

Neogene/AZN utilizes the DNA cutter, CRSPR/Cas9. While I expect that one day research will provide the solution, I have yet to come across a published paper that asserts that the concern of "random, unintended cuts of the human genome" by CRSPR/Cas9 has been resolved.

A 2018 overview of CRSPR. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6058482/